ORGANOGENESIS - der Superstar ! - 500 Beiträge pro Seite

[Frenkes]

Guten Tag zusammen,
ich gebe es offen zu - ich bin ORGANOGENESIS - PUSHER.
aber den folgenden Link sollte man sich ansehen.
Erstens weil dort Klasse Chartanalysen sofort erstellt werden.

Und zweitens weil man mal unser "Baby" Organogenesis
bewundern kann.

Weiteres seht Ihr hier im Board unter organogenesis. ( org )

Ps: Danke ParkerD für den Tip

http://quotes.barchart.com/texpert.asp?sym=ORG&code=BTDY

von Frenkes 28.08.00 14:23:39
betrifft Aktie: ORGANOGENESIS INC. DL-,01 1677318

Sorry - ich vergaß die WKN.

872428

Bitte verzeiht mir dass ich wieder pushe - irgendwann
wird man mir vielleicht dankbar sein.

[Frenkes]

Es geht weiter mit org.
Also - dranbleiben.

CANTON, Mass.--(BW HealthWire)--Sept. 5, 2000--Organogenesis Inc. (AMEX:ORG - news) today announced that US commercial sales of lead product Apligraf® were a record 1239 units in August. The number of medical centers ordering Apligraf for the first time showed continued growth, while the number of centers re-ordering Apligraf for the first time showed the greatest monthly increase to date. Apligraf is marketed by Novartis Pharmaceuticals Corporation.


US Commercial Unit Sales of Apligraf

Time Period Month Quarter
3Q98 548
4Q98 1070
1Q99 1585
2Q99 1755
3Q99 1817
4Q99 2192
1Q00 2555
2Q00 2814
July `00 912
August `00 1239

``We are beginning to see the effect of the July launch of Apligraf for diabetic foot ulcers and the product`s expanded availability to Medicare patients,`` said Philip Laughlin, President and Chief Executive Officer. ``For example, Apligraf used in a hospital outpatient setting, such as a hospital-affiliated wound care clinic, is now reimbursable under a new Medicare program that went into effect in August. In addition, this summer Novartis increased the size of the Apligraf-dedicated field force - adding twenty sales representatives.``

Organogenesis is the only tissue-engineering company to have developed and gained FDA approval for a mass-produced product containing living human cells. The Company`s product development focus includes living tissue replacements, cell-based organ assist devices and other tissue-engineered products. Lead product Apligraf - a cellular, bi-layered skin substitute - is approved and marketed for the treatment of venous leg ulcers and diabetic foot ulcers; Novartis Pharma AG has global Apligraf marketing rights. The Organogenesis research pipeline includes the VITRIX(TM) living dermal replacement product, a coronary vascular graft and a liver assist device.

Statements in the press release which are not historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties. There can be no guarantee as to the rate of development of Apligraf sales. Apligraf® is a registered trademark of Novartis.


--------------------------------------------------------------------------------
Contact:
Organogenesis Inc.
Carol Hausner
Senior Director, Corporate Communications
781-575-0775


Email this story - View most popular stories emailed


--------------------------------------------------------------------------------
More Quotes and News: Organogenesis Inc (AMEX:ORG - news)
Related News Categories: biotech, health care, medical/pharmaceutical

[gotoweb]

Scheint ganz interessant zu werden:

- Rekordzahlen bei Apligraf im April: 1813 Einheiten
- Beteiligung von Novartis.
- Quartalsverluste schrumpfen weiter.


-----------
Organogenesis Inc
http://www.organogenesis.com/

Handel in Frankfurt und Berlin
WKN 872428
EUR ca. 10,00